A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive^TM) for COVID-19 Patients

Table 5

Modified Jackson’s Symptom Severity Score.

Parameter	Active (ImmuActive^TM) group; (N = 45)	Placebo (microcrystalline cellulose) group; (N = 47)	value
Screening visit (visit 1)
Mean ± SD	4.98 ± 2.18	5.11 ± 2.29	0.7812(NS)
Minimum	2.00	1.00
Maximum	10.00	11.00
End visit
Mean ± SD	1.36 ± 1.71	1.70 ± 1.68	0.3413(NS)
Minimum	0.00	0.00
Maximum	8.00	5.00
Mean change from baseline	−3.62	−3.41
value	<0.0001	<0.0001

NS, not significant; .